Zacks Downgrades Alexza Pharmaceuticals to Neutral

Symbols: ALXA
Share

Zacks Investment Research has downgraded Alexza Pharmaceuticals (NASDAQ: ALXA) from Outperform to Neutral and has established a $1.50 price target.


 
 
< Previous
Wunderlich Downgrades MEMC Electronic Materials to Sell, PT Lowered to $3
Next >
UBS Downgrades NRG, SLAB to Neutral
Share
Printer-friendly version
Send to friend
We're Loving

Benzinga's Premium Memberships

Benzinga's News Delivered Free

Brain Trust